ObsEva has a 52 week low of $0.08 and a 52 week high of $2.14. The stock has a market capitalization of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68. ObsEva SA is a ...

ObsEva has a 52 week low of $0.08 and a 52 week high of $2.14. The company has a market cap of $7.94 million, a P/E ratio of -0.11 and a beta of 0.68. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This ...

-Yselty® for uterine fibroids: US New Drug Application submissionplanned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 ...

About ObsEva S.A. ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health ...

Primary endpoint successfully met in Phase 3PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids Phase 3 data from PRIMROSE 2 trial demonstrated ...

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by ...

Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...

Geneva, Switzerland and Boston, MA – July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Visit a quote page and your recently viewed tickers will be displayed here. Cost of Goods Sold (COGS) incl. D&A Cost of Goods Sold (COGS) incl. D&A ...